Literature DB >> 26205604

Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).

Gregory Y H Lip, Flemming Skjøth, Lars Hvilsted Rasmussen, Peter B Nielsen, Torben Bjerregaard Larsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26205604     DOI： 10.1016/j.jacc.2015.05.044

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  6 in total

1.  Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.

Authors:  Gregory Y H Lip; Flemming Skjøth; Peter Brønnum Nielsen; Jette Nordstrøm Kjældgaard; Torben Bjerregaard Larsen
Journal:  JAMA Cardiol       Date:  2017-08-01       Impact factor: 14.676

Review 2.  Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.

Authors:  Hans-Christoph Diener; James Aisenberg; Jack Ansell; Dan Atar; Günter Breithardt; John Eikelboom; Michael D Ezekowitz; Christopher B Granger; Jonathan L Halperin; Stefan H Hohnloser; Elaine M Hylek; Paulus Kirchhof; Deirdre A Lane; Freek W A Verheugt; Roland Veltkamp; Gregory Y H Lip
Journal:  Eur Heart J       Date:  2017-03-21       Impact factor: 29.983

3.  Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study.

Authors:  Peter Brønnum Nielsen; Torben Bjerregaard Larsen; Flemming Skjøth; Thure Filskov Overvad; Gregory Y H Lip
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

4.  2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.

Authors:  Chern-En Chiang; Ken Okumura; Shu Zhang; Tze-Fan Chao; Chung-Wah Siu; Toon Wei Lim; Anil Saxena; Yoshihide Takahashi; Wee Siong Teo
Journal:  J Arrhythm       Date:  2017-06-27

5.  Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.

Authors:  Michał Mazurek; Menno V Huisman; Kenneth J Rothman; Miney Paquette; Christine Teutsch; Hans-Christoph Diener; Sergio J Dubner; Jonathan L Halperin; Chang Sheng Ma; Kristina Zint; Amelie Elsaesser; Shihai Lu; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2017-12-06       Impact factor: 5.249

6.  Risk of ischemic stroke and utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation.

Authors:  Maria Tomasdottir; Leif Friberg; Ziad Hijazi; Johan Lindbäck; Jonas Oldgren
Journal:  Clin Cardiol       Date:  2019-09-06       Impact factor: 2.882
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.